Illumina, Inc. (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc. (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations. Core Illumina's products and services serve customers in the research, clinical and applied markets, and enable the adoption of a range of genomic solutions. The Company's portfolio of integrated systems, consumables and analysis tools addresses the range of genomic complexity, price points, and throughput, enabling customers to select the solution for their research or clinical challenge. The Company provides reproductive-health solutions, including noninvasive prenatal testing (NIPT), preimplantation genetic screening and diagnosis, and neonatal and genetic health testing.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Advanced Medical Equipment & Technology - NEC
- Sub-Industry: Life Sciences Tools & Services
- Symbol: NASDAQ:ILMN
- CUSIP: 45232710
- Web: www.illumina.com
Capitalization:- Market Cap: $25.38648 billion
- Outstanding Shares: 146,000,000
Average Prices:- 50 Day Moving Avg: $175.68
- 200 Day Moving Avg: $170.24
- 52 Week Range: $119.37 - $189.48
P/E:- Trailing P/E Ratio: 34.80
- Foreward P/E Ratio: 39.35
- P/E Growth: 3.40
Sales & Book Value:- Annual Revenue: $2.42 billion
- Price / Sales: 10.38
- Book Value: $17.47 per share
- Price / Book: 9.84
Profitability:- EBIDTA: $678.78 million
- Net Margins: 30.75%
- Return on Equity: 21.21%
- Return on Assets: 11.52%
Debt:- Debt-to-Equity Ratio: 0.41%
- Current Ratio: 3.49%
- Quick Ratio: 3.08%
Misc:- Average Volume: 987,354 shs.
- Beta: 0.84
- Short Ratio: 3.92
Frequently Asked Questions for Illumina (NASDAQ:ILMN)
What is Illumina's stock symbol?
Illumina trades on the NASDAQ under the ticker symbol "ILMN."
How were Illumina's earnings last quarter?
Illumina, Inc. (NASDAQ:ILMN) announced its earnings results on Tuesday, April, 25th. The company reported $0.64 earnings per share for the quarter, meeting the consensus estimate of $0.64. The firm earned $598 million during the quarter, compared to the consensus estimate of $590.51 million. Illumina had a return on equity of 21.21% and a net margin of 30.75%. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.71 EPS. View Illumina's Earnings History.
What guidance has Illumina issued on next quarter's earnings?
Illumina issued an update on its FY17 earnings guidance on Tuesday, April, 25th. The company provided earnings per share guidance of $3.60-3.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $3.65. Illumina also updated its Q2 guidance to $0.65-0.70 EPS.
Where is Illumina's stock going? Where will Illumina's stock price be in 2017?
20 equities research analysts have issued twelve-month target prices for Illumina's stock. Their predictions range from $116.00 to $200.00. On average, they expect Illumina's stock price to reach $162.42 in the next year. View Analyst Ratings for Illumina.
Who are some of Illumina's key competitors?
Some companies that are related to Illumina include Boston Scientific Corporation (BSX), Intuitive Surgical (ISRG), Koninklijke Philips N.V. (PHG), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), Hologic (HOLX), ResMed (RMD), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR), Accelerate Diagnostics (AXDX), Natus Medical Incorporated (BABY), Quidel Corporation (QDEL) and ABAXIS (ABAX).
Who are Illumina's key executives?
Illumina's management team includes the folowing people:
- Jay T. Flatley, Executive Chairman of the Board
- Francis A. deSouza, President, Chief Executive Officer, Director
- Sam Samad, Chief Financial Officer, Senior Vice President
- Marc A. Stapley, Executive Vice President, Chief Administrative Officer
- Garret Hampton Ph.D., Executive Vice President - Clinical Genomics
- Omead Ostadan, Executive Vice President - Operations, Products and Strategy
- Mostafa Ronaghi Ph.D., Chief Technology Officer, Senior Vice President
- Charles E. Dadswell, Senior Vice President, General Counsel, Secretary
- Mark Van Oene, Senior Vice President, Chief Commercial Officer
- Arthur Blaine Bowman, Lead Independent Director
Who owns Illumina stock?
Illumina's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Douglas Lane & Associates LLC (0.33%), Chevy Chase Trust Holdings Inc. (0.26%), Rockefeller Financial Services Inc. (0.23%), State Treasurer State of Michigan (0.18%), National Pension Service (0.09%) and Gateway Investment Advisers LLC (0.07%). Company insiders that own Illumina stock include A Blaine Bowman, Charles Dadswell, Christian O Henry, Daniel Bradbury, David R Walt, Frances Arnold, Jay T Flatley, Karin Eastham, Marc Stapley, Michel Bouchard, Nicholas Naclerio, Omead Ostadan, Paul L Bianchi, Robert S Epstein and Roy A Whitfield. View Institutional Ownership Trends for Illumina.
Who sold Illumina stock? Who is selling Illumina stock?
Illumina's stock was sold by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Rockefeller Financial Services Inc., Creative Planning, Gateway Investment Advisers LLC, Exxonmobil Investment Management Inc. TX, Douglas Lane & Associates LLC, DnB Asset Management AS and Cottage Street Advisors LLC. Company insiders that have sold Illumina stock in the last year include A Blaine Bowman, Charles Dadswell, Daniel Bradbury, Frances Arnold, Jay T Flatley, Marc Stapley, Michel Bouchard, Omead Ostadan, Robert S Epstein and Roy A Whitfield. View Insider Buying and Selling for Illumina.
Who bought Illumina stock? Who is buying Illumina stock?
Illumina's stock was acquired by a variety of institutional investors in the last quarter, including Chevy Chase Trust Holdings Inc., Mn Services Vermogensbeheer B.V., Aperio Group LLC, National Pension Service, Private Asset Management Inc., State of Alaska Department of Revenue, CrestPoint Capital Management LLC and Nisa Investment Advisors LLC. View Insider Buying and Selling for Illumina.
How do I buy Illumina stock?
Shares of Illumina can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Illumina's stock price today?
One share of Illumina stock can currently be purchased for approximately $171.97.
MarketBeat Community Rating for Illumina (NASDAQ ILMN)MarketBeat's community ratings are surveys of what our community members think about Illumina and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Illumina (NASDAQ:ILMN) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Sell Ratings, 9 Hold Ratings, 8 Buy Ratings |
| Consensus Rating: | Hold (Score: 2.25) |
| Consensus Price Target: | $162.42 (5.56% downside) |
Analysts' Ratings History for Illumina (NASDAQ:ILMN)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 7/19/2017 | Barclays PLC | Reiterated Rating | Hold | $150.00 | Low |  |
| 7/10/2017 | Morgan Stanley | Reiterated Rating | Underweight | $115.00 -> $122.00 | High | |
| 4/29/2017 | Deutsche Bank AG | Reiterated Rating | Hold | $165.00 -> $175.00 | Low | |
| 4/26/2017 | Cowen and Company | Reiterated Rating | Outperform | $200.00 | High | |
| 4/26/2017 | Cantor Fitzgerald | Boost Price Target | Neutral -> Neutral | $155.00 -> $170.00 | High | |
| 4/14/2017 | Piper Jaffray Companies | Reiterated Rating | Overweight | $170.00 -> $187.00 | N/A | |
| 4/11/2017 | Bank of America Corporation | Boost Price Target | Buy | $175.00 -> $195.00 | Low | |
| 4/5/2017 | Leerink Swann | Reiterated Rating | Buy | | Medium | |
| 3/19/2017 | BTIG Research | Reiterated Rating | Hold | | Medium | |
| 2/27/2017 | Evercore ISI | Upgrade | Hold -> Buy | $190.00 | N/A | |
| 2/21/2017 | Canaccord Genuity | Reiterated Rating | Hold | $150.00 | N/A | |
| 1/12/2017 | Robert W. Baird | Reiterated Rating | Neutral | $147.00 -> $153.00 | N/A | |
| 1/6/2017 | Janney Montgomery Scott | Reiterated Rating | Neutral -> Sell | $125.00 | N/A | |
| 1/6/2017 | CL King | Upgrade | Neutral -> Buy | | N/A | |
| 11/2/2016 | First Analysis | Downgrade | Equal Weight -> Underweight | $130.00 -> $116.00 | N/A | |
| 10/14/2016 | Argus | Reiterated Rating | Buy | $205.00 -> $170.00 | N/A | |
| 10/12/2016 | Wells Fargo & Company | Reiterated Rating | Market Perform | $150.00 -> $137.50 | N/A | |
| 10/11/2016 | Citigroup Inc. | Downgrade | Buy -> Neutral | $190.00 -> $140.00 | N/A | |
| 7/27/2016 | J P Morgan Chase & Co | Boost Price Target | Overweight | $185.00 -> $200.00 | N/A | |
| 7/27/2016 | Mizuho | Boost Price Target | Neutral | $138.00 -> $148.00 | N/A | |
| 5/4/2016 | Stifel Nicolaus | Reiterated Rating | Buy | $215.00 -> $160.00 | N/A | |
| 5/3/2016 | Nomura | Lower Price Target | Buy | $210.00 -> $180.00 | N/A | |
| 4/22/2016 | Avondale Partners | Reiterated Rating | Market Perform | $175.00 -> $160.00 | N/A | |
| 3/23/2016 | Goldman Sachs Group, Inc. (The) | Lower Price Target | | $141.00 | N/A | |
| 10/21/2015 | Wedbush | Boost Price Target | Outperform | $150.00 -> $160.00 | N/A | |
| 10/8/2015 | William Blair | Reiterated Rating | Buy | | N/A | |
(Data available from 7/21/2015 forward)
Earnings History for Illumina (NASDAQ:ILMN)Earnings History by Quarter for Illumina (NASDAQ ILMN)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 4/25/2017 | Q1 2017 | $0.64 | $0.64 | $590.51 million | $598.00 million | View | N/A | |
| 1/31/2017 | Q416 | $0.82 | $0.85 | $612.50 million | $619.00 million | View | Listen | |
| 11/1/2016 | Q316 | $0.87 | $0.97 | $628.06 million | $607.00 million | View | Listen | |
| 7/26/2016 | Q2 | $0.73 | $0.86 | $31.91 million | $600.00 million | View | Listen | |
| 5/3/2016 | Q1 | $0.74 | $0.71 | $596.33 million | $572.00 million | View | Listen | |
| 2/2/2016 | Q415 | $0.82 | $0.81 | $576.39 million | $591.50 million | View | Listen | |
| 10/20/2015 | Q315 | $0.79 | $0.80 | $568.60 million | $550.00 million | View | Listen | |
| 7/21/2015 | Q215 | $0.77 | $0.80 | $541.05 million | $539.00 million | View | Listen | |
| 4/21/2015 | Q115 | $0.72 | $0.91 | $524.35 million | $539.00 million | View | Listen | |
| 1/27/2015 | Q414 | $0.78 | $0.87 | $503.83 million | $512.00 million | View | Listen | |
| 10/20/2014 | Q314 | $0.56 | $0.77 | $451.20 million | $481.00 million | View | Listen | |
| 7/23/2014 | Q214 | $0.51 | $0.57 | $426.50 million | $448.00 million | View | Listen | |
| 4/22/2014 | Q114 | $0.44 | $0.53 | $391.50 million | $421.00 million | View | Listen | |
| 1/28/2014 | Q413 | $0.44 | $0.45 | $382.06 million | $387.00 million | View | Listen | |
| 10/21/2013 | Q313 | $0.40 | $0.45 | $343.42 million | $357.00 million | View | Listen | |
| 7/23/2013 | Q2 2013 | $0.40 | $0.43 | $331.77 million | $346.09 million | View | Listen | |
| 4/22/2013 | Q1 2013 | $0.39 | $0.46 | $310.64 million | $330.96 million | View | Listen | |
| 1/28/2013 | Q4 2012 | $0.41 | $0.42 | $303.13 million | $309.30 million | View | Listen | |
| 10/23/2012 | | $0.39 | $0.41 | | | View | N/A | |
| 7/24/2012 | | $0.36 | $0.40 | | | View | N/A | |
| 4/23/2012 | | $0.32 | $0.36 | | | View | N/A | |
| 2/7/2012 | | $0.30 | $0.35 | | | View | N/A | |
| 10/25/2011 | | $0.23 | $0.22 | | | View | N/A | |
| 4/26/2011 | | $0.31 | $0.35 | | | View | N/A | |
| 2/8/2011 | | $0.29 | $0.29 | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Illumina (NASDAQ:ILMN)2017 EPS Consensus Estimate: $3.63
2018 EPS Consensus Estimate: $4.36
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.63 | $0.82 | $0.69 |
| Q2 2017 | 3 | $0.65 | $0.85 | $0.72 |
| Q3 2017 | 3 | $0.95 | $1.14 | $1.06 |
| Q4 2017 | 3 | $1.04 | $1.27 | $1.16 |
| Q1 2018 | 3 | $0.76 | $1.04 | $0.94 |
| Q2 2018 | 2 | $1.05 | $1.07 | $1.06 |
| Q3 2018 | 2 | $1.12 | $1.17 | $1.15 |
| Q4 2018 | 2 | $1.17 | $1.26 | $1.22 |
(Data provided by Zacks Investment Research)
Dividend History for Illumina (NASDAQ:ILMN)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Illumina (NASDAQ:ILMN)Insider Ownership Percentage: 1.60%
Institutional Ownership Percentage: 93.73%
Insider Trades by Quarter for Illumina (NASDAQ:ILMN)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 7/18/2017 | Jay T Flatley | Director | Sell | 15,000 | $170.77 | $2,561,550.00 | |
| 7/14/2017 | Marc Stapley | EVP | Sell | 2,000 | $173.56 | $347,120.00 | |
| 7/7/2017 | Omead Ostadan | EVP | Sell | 1,672 | $172.73 | $288,804.56 | |
| 7/5/2017 | Jay T Flatley | Director | Sell | 15,000 | $172.92 | $2,593,800.00 | |
| 7/3/2017 | Charles Dadswell | SVP | Sell | 145 | $174.24 | $25,264.80 | |
| 6/23/2017 | Michel Bouchard | Insider | Sell | 246 | $185.00 | $45,510.00 | |
| 6/22/2017 | Jay T Flatley | Director | Sell | 20,000 | $178.21 | $3,564,200.00 | |
| 6/12/2017 | Marc Stapley | EVP | Sell | 2,000 | $170.85 | $341,700.00 | |
| 6/8/2017 | Michel Bouchard | Insider | Sell | 246 | $178.91 | $44,011.86 | |
| 6/6/2017 | Jay T Flatley | Director | Sell | 20,000 | $180.24 | $3,604,800.00 | |
| 6/5/2017 | Charles Dadswell | SVP | Sell | 145 | $184.75 | $26,788.75 | |
| 6/1/2017 | Jay T Flatley | Director | Sell | 3,320 | $180.55 | $599,426.00 | |
| 5/25/2017 | Frances Arnold | Director | Sell | 825 | $174.77 | $144,185.25 | |
| 5/23/2017 | Jay T Flatley | Director | Sell | 15,000 | $175.53 | $2,632,950.00 | |
| 5/10/2017 | A Blaine Bowman | Director | Sell | 2,300 | $181.61 | $417,703.00 | |
| 5/9/2017 | Jay T Flatley | Director | Sell | 20,000 | $184.14 | $3,682,800.00 | |
| 5/9/2017 | Michel Bouchard | Insider | Sell | 5,740 | $184.68 | $1,060,063.20 | |
| 5/3/2017 | Charles Dadswell | SVP | Sell | 1,609 | $187.07 | $300,995.63 | |
| 4/12/2017 | A Blaine Bowman | Director | Sell | 3,000 | $172.72 | $518,160.00 | |
| 4/7/2017 | Daniel Bradbury | Director | Sell | 600 | $172.79 | $103,674.00 | |
| 3/24/2017 | Omead Ostadan | EVP | Sell | 1,672 | $170.00 | $284,240.00 | |
| 3/21/2017 | Daniel Bradbury | Director | Sell | 600 | $163.56 | $98,136.00 | |
| 2/17/2017 | Daniel Bradbury | Director | Sell | 600 | $162.80 | $97,680.00 | |
| 2/13/2017 | Omead Ostadan | EVP | Sell | 2,173 | $163.10 | $354,416.30 | |
| 2/8/2017 | A Blaine Bowman | Director | Sell | 3,000 | $162.74 | $488,220.00 | |
| 2/6/2017 | Charles Dadswell | SVP | Sell | 572 | $161.26 | $92,240.72 | |
| 1/30/2017 | Omead Ostadan | EVP | Sell | 259 | $160.90 | $41,673.10 | |
| 1/19/2017 | Omead Ostadan | EVP | Sell | 2,378 | $160.06 | $380,622.68 | |
| 1/11/2017 | A Blaine Bowman | Director | Sell | 3,000 | $162.89 | $488,670.00 | |
| 1/10/2017 | Charles Dadswell | SVP | Sell | 116 | $161.60 | $18,745.60 | |
| 1/4/2017 | Daniel Bradbury | Director | Sell | 600 | $135.01 | $81,006.00 | |
| 12/15/2016 | Omead Ostadan | EVP | Sell | 2,000 | $126.16 | $252,320.00 | |
| 12/12/2016 | Daniel Bradbury | Director | Sell | 600 | $123.42 | $74,052.00 | |
| 12/8/2016 | Omead Ostadan | EVP | Sell | 3,000 | $121.63 | $364,890.00 | |
| 12/1/2016 | Omead Ostadan | EVP | Sell | 3,000 | $133.30 | $399,900.00 | |
| 11/14/2016 | Daniel Bradbury | Director | Sell | 600 | $136.34 | $81,804.00 | |
| 10/7/2016 | Daniel Bradbury | Director | Sell | 600 | $184.36 | $110,616.00 | |
| 10/4/2016 | Charles Dadswell | SVP | Sell | 116 | $182.38 | $21,156.08 | |
| 9/20/2016 | Robert S Epstein | Director | Sell | 300 | $174.29 | $52,287.00 | |
| 9/15/2016 | Marc Stapley | EVP | Sell | 1,270 | $172.87 | $219,544.90 | |
| 9/14/2016 | Daniel Bradbury | Director | Sell | 600 | $171.25 | $102,750.00 | |
| 8/23/2016 | Jay T Flatley | Director | Sell | 20,000 | $172.99 | $3,459,800.00 | |
| 8/22/2016 | Robert S Epstein | Director | Sell | 300 | $170.27 | $51,081.00 | |
| 8/17/2016 | Daniel Bradbury | Director | Sell | 600 | $168.42 | $101,052.00 | |
| 8/15/2016 | Jay T Flatley | Director | Sell | 10,000 | $170.00 | $1,700,000.00 | |
| 8/12/2016 | Roy A Whitfield | Director | Sell | 4,000 | $167.22 | $668,880.00 | |
| 8/9/2016 | Jay T Flatley | Director | Sell | 10,000 | $165.97 | $1,659,700.00 | |
| 8/1/2016 | Jay T Flatley | Director | Sell | 10,000 | $170.00 | $1,700,000.00 | |
| 7/27/2016 | Charles Dadswell | SVP | Sell | 8,632 | $155.00 | $1,337,960.00 | |
| 7/26/2016 | Jay T Flatley | Director | Sell | 10,000 | $150.00 | $1,500,000.00 | |
| 7/20/2016 | Robert S Epstein | Director | Sell | 1,200 | $150.00 | $180,000.00 | |
| 7/18/2016 | Jay T Flatley | Director | Sell | 10,000 | $150.00 | $1,500,000.00 | |
| 7/14/2016 | A Blaine Bowman | Director | Sell | 5,000 | $147.14 | $735,700.00 | |
| 7/11/2016 | Christian O Henry | EVP | Sell | 716 | $141.89 | $101,593.24 | |
| 6/16/2016 | A Blaine Bowman | Director | Sell | 5,000 | $135.08 | $675,400.00 | |
| 6/15/2016 | Christian O Henry | EVP | Sell | 2,141 | $137.90 | $295,243.90 | |
| 6/13/2016 | Roy A Whitfield | Director | Sell | 3,800 | $140.44 | $533,672.00 | |
| 6/1/2016 | Karin Eastham | Director | Sell | 5,000 | $145.35 | $726,750.00 | |
| 5/25/2016 | Christian O Henry | EVP | Sell | 2,141 | $144.73 | $309,866.93 | |
| 5/17/2016 | Christian O Henry | EVP | Sell | 2,141 | $140.84 | $301,538.44 | |
| 5/12/2016 | A Blaine Bowman | Director | Sell | 5,000 | $137.11 | $685,550.00 | |
| 4/27/2016 | Christian O Henry | EVP | Sell | 2,141 | $138.46 | $296,442.86 | |
| 4/18/2016 | Christian O Henry | EVP | Sell | 2,141 | $176.01 | $376,837.41 | |
| 4/18/2016 | Paul L Bianchi | VP | Sell | 1,884 | $175.00 | $329,700.00 | |
| 4/14/2016 | A Blaine Bowman | Director | Sell | 5,000 | $172.94 | $864,700.00 | |
| 4/13/2016 | Christian O Henry | EVP | Sell | 12,500 | $175.00 | $2,187,500.00 | |
| 4/13/2016 | Paul L Bianchi | VP | Sell | 6,681 | $175.00 | $1,169,175.00 | |
| 4/12/2016 | Jay T Flatley | CEO | Sell | 20,000 | $170.05 | $3,401,000.00 | |
| 4/12/2016 | Roy A Whitfield | Director | Sell | 4,000 | $170.00 | $680,000.00 | |
| 4/7/2016 | David R Walt | Director | Sell | 4,000 | $168.90 | $675,600.00 | |
| 4/5/2016 | Christian O Henry | EVP | Sell | 2,141 | $166.07 | $355,555.87 | |
| 4/4/2016 | Charles Dadswell | SVP | Sell | 8,382 | $167.81 | $1,406,583.42 | |
| 3/23/2016 | Christian O Henry | EVP | Sell | 2,141 | $155.05 | $331,962.05 | |
| 3/22/2016 | Jay T Flatley | CEO | Sell | 10,000 | $154.18 | $1,541,800.00 | |
| 3/21/2016 | Daniel Bradbury | Director | Sell | 1,200 | $155.63 | $186,756.00 | |
| 3/21/2016 | Nicholas Naclerio | SVP | Sell | 4,520 | $154.25 | $697,210.00 | |
| 3/17/2016 | A Blaine Bowman | Director | Sell | 5,000 | $145.24 | $726,200.00 | |
| 3/15/2016 | David R Walt | Director | Sell | 4,000 | $149.99 | $599,960.00 | |
| 3/14/2016 | Christian O Henry | EVP | Sell | 5,892 | $155.91 | $918,621.72 | |
| 3/8/2016 | Charles Dadswell | SVP | Sell | 8,382 | $155.63 | $1,304,490.66 | |
| 3/8/2016 | Jay T Flatley | CEO | Sell | 10,000 | $154.49 | $1,544,900.00 | |
| 3/8/2016 | Omead Ostadan | EVP | Sell | 4,516 | $156.09 | $704,902.44 | |
| 3/7/2016 | Charles Dadswell | SVP | Sell | 116 | $155.00 | $17,980.00 | |
| 2/23/2016 | Jay T Flatley | CEO | Sell | 10,000 | $152.49 | $1,524,900.00 | |
| 2/17/2016 | Daniel Bradbury | Director | Sell | 1,700 | $154.74 | $263,058.00 | |
| 2/12/2016 | Roy A. Whitfield | Director | Sell | 3,750 | $140.30 | $526,125.00 | |
| 2/1/2016 | Omead Ostadan | EVP | Sell | 1,108 | $156.73 | $173,656.84 | |
| 1/26/2016 | Jay T. Flatley | CEO | Sell | 20,000 | $171.70 | $3,434,000.00 | |
| 1/13/2016 | Jay T. Flatley | CEO | Sell | 20,000 | $168.81 | $3,376,200.00 | |
| 1/4/2016 | Daniel Bradbury | Director | Sell | 1,700 | $182.80 | $310,760.00 | |
| 12/28/2015 | Charles Dadswell | SVP | Sell | 168 | $188.63 | $31,689.84 | |
| 12/22/2015 | Jay T. Flatley | CEO | Sell | 25,000 | $185.38 | $4,634,500.00 | |
| 12/14/2015 | Roy A. Whitfield | Director | Sell | 3,750 | $175.07 | $656,512.50 | |
| 12/11/2015 | Omead Ostadan | EVP | Sell | 260 | $179.90 | $46,774.00 | |
| 12/11/2015 | Paul L Bianchi | VP | Sell | 197 | $179.90 | $35,440.30 | |
| 12/10/2015 | Daniel Bradbury | Director | Sell | 1,700 | $182.37 | $310,029.00 | |
| 12/8/2015 | Jay T. Flatley | CEO | Sell | 25,000 | $177.11 | $4,427,750.00 | |
| 11/27/2015 | Robert S Epstein | Director | Sell | 1,000 | $185.56 | $185,560.00 | |
| 11/25/2015 | Jay T. Flatley | CEO | Sell | 5,000 | $180.00 | $900,000.00 | |
| 11/24/2015 | Jay T. Flatley | CEO | Sell | 20,000 | $173.27 | $3,465,400.00 | |
| 11/16/2015 | Jay T. Flatley | CEO | Sell | 10,000 | $170.00 | $1,700,000.00 | |
| 11/10/2015 | Daniel Bradbury | Director | Sell | 1,700 | $154.03 | $261,851.00 | |
| 11/10/2015 | Jay T. Flatley | CEO | Sell | 10,000 | $154.58 | $1,545,800.00 | |
| 11/3/2015 | Charles Dadswell | SVP | Sell | 158 | $150.00 | $23,700.00 | |
| 10/15/2015 | Jay T. Flatley | CEO | Sell | 10,000 | $150.00 | $1,500,000.00 | |
| 10/7/2015 | Daniel Bradbury | Director | Sell | 1,700 | $145.81 | $247,877.00 | |
| 9/29/2015 | David R Walt | Director | Sell | 2,000 | $171.65 | $343,300.00 | |
| 9/22/2015 | Jay T. Flatley | CEO | Sell | 25,000 | $192.79 | $4,819,750.00 | |
| 9/15/2015 | David R Walt | Director | Sell | 2,000 | $206.45 | $412,900.00 | |
| 9/14/2015 | Daniel Bradbury | Director | Sell | 1,700 | $203.89 | $346,613.00 | |
| 9/9/2015 | Paul L. Bianchi | VP | Sell | 1,245 | $199.32 | $248,153.40 | |
| 9/8/2015 | Jay T. Flatley | CEO | Sell | 25,000 | $194.87 | $4,871,750.00 | |
| 9/8/2015 | Karin Eastham | Director | Sell | 4,300 | $195.76 | $841,768.00 | |
| 9/4/2015 | Roy A. Whitfield | Director | Sell | 4,500 | $192.63 | $866,835.00 | |
| 9/1/2015 | David R Walt | Director | Sell | 2,000 | $195.08 | $390,160.00 | |
| 8/27/2015 | Jay T. Flatley | CEO | Sell | 25,000 | $200.16 | $5,004,000.00 | |
| 8/18/2015 | David R Walt | Director | Sell | 2,000 | $206.89 | $413,780.00 | |
| 8/17/2015 | Daniel Bradbury | Director | Sell | 1,700 | $208.14 | $353,838.00 | |
| 8/13/2015 | Jay T Flatley | CEO | Sell | 25,000 | $207.85 | $5,196,250.00 | |
| 8/5/2015 | Roy A. Whitfield | Director | Sell | 4,500 | $215.22 | $968,490.00 | |
| 7/24/2015 | A Blaine Bowman | Director | Sell | 3,000 | $221.47 | $664,410.00 | |
| 7/23/2015 | Jay T Flatley | CEO | Sell | 25,000 | $214.87 | $5,371,750.00 | |
| 7/21/2015 | David R Walt | Director | Sell | 12,000 | $235.24 | $2,822,880.00 | |
| 7/17/2015 | Mostafa Ronaghi | SVP | Sell | 1,200 | $235.00 | $282,000.00 | |
| 7/16/2015 | Christian O Henry | SVP | Sell | 5,390 | $229.61 | $1,237,597.90 | |
| 7/15/2015 | Mostafa Ronaghi | SVP | Sell | 3,000 | $227.19 | $681,570.00 | |
| 7/14/2015 | David R Walt | Director | Sell | 10,000 | $227.39 | $2,273,900.00 | |
| 7/13/2015 | Marc Stapley | CFO | Sell | 3,000 | $214.90 | $644,700.00 | |
| 7/13/2015 | Michel Bouchard | CAO | Sell | 1,400 | $222.75 | $311,850.00 | |
| 7/10/2015 | Omead Ostadan | SVP | Sell | 1,110 | $219.81 | $243,989.10 | |
| 7/10/2015 | Robert S Epstein | Director | Sell | 2,000 | $219.81 | $439,620.00 | |
| 7/9/2015 | Jay T Flatley | CEO | Sell | 25,000 | $218.10 | $5,452,500.00 | |
| 7/7/2015 | David R Walt | Director | Sell | 10,000 | $220.22 | $2,202,200.00 | |
| 7/6/2015 | Daniel Bradbury | Director | Sell | 1,700 | $219.70 | $373,490.00 | |
| 6/30/2015 | David R Walt | Director | Sell | 10,000 | $217.64 | $2,176,400.00 | |
| 6/25/2015 | Jay T Flatley | CEO | Sell | 25,000 | $220.34 | $5,508,500.00 | |
| 6/24/2015 | A Blaine Bowman | Director | Sell | 3,000 | $221.43 | $664,290.00 | |
| 6/24/2015 | Christian O Henry | SVP | Sell | 5,084 | $221.07 | $1,123,919.88 | |
| 6/23/2015 | David R Walt | Director | Sell | 12,000 | $220.11 | $2,641,320.00 | |
| 6/17/2015 | Christian O Henry | SVP | Sell | 3,751 | $215.71 | $809,128.21 | |
| 6/16/2015 | David R Walt | Director | Sell | 10,000 | $215.14 | $2,151,400.00 | |
| 6/15/2015 | Nicholas Naclerio | SVP | Sell | 6,590 | $214.33 | $1,412,434.70 | |
| 6/15/2015 | Paul L Bianchi | VP | Sell | 3,408 | $215.83 | $735,548.64 | |
| 6/12/2015 | Marc Stapley | CFO | Sell | 3,000 | $214.90 | $644,700.00 | |
| 6/12/2015 | Michel Bouchard | CAO | Sell | 1,400 | $216.11 | $302,554.00 | |
| 6/11/2015 | Jay T Flatley | CEO | Sell | 25,000 | $216.41 | $5,410,250.00 | |
| 6/10/2015 | Christian O Henry | SVP | Sell | 10,000 | $214.94 | $2,149,400.00 | |
| 6/10/2015 | Robert S Epstein | Director | Sell | 2,000 | $214.24 | $428,480.00 | |
| 6/5/2015 | Roy A Whitfield | Director | Sell | 4,500 | $207.49 | $933,705.00 | |
| 6/2/2015 | David R Walt | Director | Sell | 10,000 | $204.42 | $2,044,200.00 | |
| 6/1/2015 | Karin Eastham | Director | Sell | 5,000 | $205.24 | $1,026,200.00 | |
| 5/29/2015 | Daniel Bradbury | Director | Sell | 1,700 | $206.62 | $351,254.00 | |
| 5/28/2015 | Jay T Flatley | CEO | Sell | 25,000 | $208.78 | $5,219,500.00 | |
| 5/22/2015 | A Blaine Bowman | Director | Sell | 3,000 | $204.58 | $613,740.00 | |
| 5/19/2015 | David R Walt | Director | Sell | 10,000 | $202.00 | $2,020,000.00 | |
| 5/14/2015 | Christian O Henry | SVP | Sell | 3,751 | $198.52 | $744,648.52 | |
| 5/14/2015 | Jay T Flatley | CEO | Sell | 25,000 | $197.76 | $4,944,000.00 | |
| 5/13/2015 | Paul L Bianchi | VP | Sell | 3,356 | $197.14 | $661,601.84 | |
| 5/11/2015 | Robert S Epstein | Director | Sell | 2,000 | $196.49 | $392,980.00 | |
| 4/28/2015 | David R Walt | Director | Sell | 7,000 | $183.88 | $1,287,160.00 | |
| 4/24/2015 | A Blaine Bowman | Director | Sell | 3,000 | $190.73 | $572,190.00 | |
| 4/23/2015 | Jay T Flatley | CEO | Sell | 25,000 | $189.57 | $4,739,250.00 | |
| 4/21/2015 | David R Walt | Director | Sell | 10,000 | $197.95 | $1,979,500.00 | |
| 4/15/2015 | Christian O Henry | SVP | Sell | 3,751 | $189.02 | $709,014.02 | |
| 4/14/2015 | David R Walt | Director | Sell | 7,000 | $188.23 | $1,317,610.00 | |
| 4/13/2015 | Marc Stapley | CFO | Sell | 3,000 | $190.12 | $570,360.00 | |
| 4/13/2015 | Michel Bouchard | CAO | Sell | 1,400 | $188.61 | $264,054.00 | |
| 4/13/2015 | Paul L Bianchi | VP | Sell | 3,390 | $187.22 | $634,675.80 | |
| 4/10/2015 | Robert S Epstein | Director | Sell | 2,000 | $186.99 | $373,980.00 | |
| 4/9/2015 | Jay T Flatley | CEO | Sell | 25,000 | $184.55 | $4,613,750.00 | |
| 4/8/2015 | Daniel Bradbury | Director | Sell | 1,700 | $185.32 | $315,044.00 | |
| 4/7/2015 | David R Walt | Director | Sell | 5,000 | $184.28 | $921,400.00 | |
| 4/6/2015 | Roy A Whitfield | Director | Sell | 4,600 | $181.32 | $834,072.00 | |
| 3/26/2015 | Jay T Flatley | CEO | Sell | 25,000 | $181.34 | $4,533,500.00 | |
| 3/24/2015 | David R Walt | Director | Sell | 5,000 | $192.16 | $960,800.00 | |
| 3/17/2015 | A Blaine Bowman | Director | Sell | 3,000 | $192.30 | $576,900.00 | |
| 3/16/2015 | Gerald Moeller | Director | Sell | 2,700 | $193.36 | $522,072.00 | |
| 3/16/2015 | Nicholas Naclerio | SVP | Sell | 6,590 | $193.94 | $1,278,064.60 | |
| 3/13/2015 | Paul L Bianchi | VP | Sell | 3,390 | $186.67 | $632,811.30 | |
| 3/12/2015 | Marc Stapley | CFO | Sell | 3,314 | $189.01 | $626,379.14 | |
| 3/10/2015 | Richard Klausner | SVP | Sell | 1,186 | $191.75 | $227,415.50 | |
| 3/10/2015 | Robert S Epstein | Director | Sell | 3,000 | $191.75 | $575,250.00 | |
| 2/26/2015 | Jay T Flatley | CEO | Sell | 25,000 | $195.73 | $4,893,250.00 | |
| 2/12/2015 | Jay T Flatley | CEO | Sell | 25,000 | $194.64 | $4,866,000.00 | |
| 2/3/2015 | David R Walt | Director | Sell | 7,000 | $190.89 | $1,336,230.00 | |
| 2/2/2015 | Karin Eastham | Director | Sell | 10,000 | $192.77 | $1,927,700.00 | |
| 2/2/2015 | Nicholas Naclerio | SVP | Sell | 15,250 | $194.37 | $2,964,142.50 | |
| 1/27/2015 | Charles Dadswell | SVP | Sell | 224 | $198.90 | $44,553.60 | |
| 1/27/2015 | David R Walt | Director | Sell | 4,000 | $201.76 | $807,040.00 | |
| 1/22/2015 | Jay T Flatley | CEO | Sell | 25,000 | $188.48 | $4,712,000.00 | |
| 1/20/2015 | William H Rastetter | Director | Sell | 16,000 | $188.99 | $3,023,840.00 | |
| 1/15/2015 | Marc Stapley | CFO | Sell | 1,422 | $181.62 | $258,263.64 | |
| 1/8/2015 | Jay T Flatley | CEO | Sell | 25,000 | $197.62 | $4,940,500.00 | |
| 1/6/2015 | David R Walt | Director | Sell | 6,000 | $188.55 | $1,131,300.00 | |
| 1/2/2015 | Karin Eastham | Director | Sell | 10,000 | $185.63 | $1,856,300.00 | |
| 12/30/2014 | David R Walt | Director | Sell | 5,000 | $186.95 | $934,750.00 | |
| 12/29/2014 | Gerald Moeller | Director | Sell | 8,000 | $187.05 | $1,496,400.00 | |
| 12/26/2014 | Jay T Flatley | CEO | Sell | 25,000 | $186.71 | $4,667,750.00 | |
| 12/23/2014 | David R Walt | Director | Sell | 7,000 | $184.55 | $1,291,850.00 | |
| 12/16/2014 | David R Walt | Director | Sell | 5,000 | $178.35 | $891,750.00 | |
| 12/15/2014 | Marc Stapley | CFO | Sell | 1,422 | $181.09 | $257,509.98 | |
| 12/11/2014 | Jay T Flatley | CEO | Sell | 25,000 | $185.79 | $4,644,750.00 | |
| 12/9/2014 | David R Walt | Director | Sell | 7,000 | $186.75 | $1,307,250.00 | |
| 12/8/2014 | Daniel Bradbury | Director | Sell | 1,600 | $190.14 | $304,224.00 | |
| 12/4/2014 | Karin Eastham | Director | Sell | 10,000 | $191.87 | $1,918,700.00 | |
| 12/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $188.46 | $1,884,600.00 | |
| 11/26/2014 | Paul L Bianchi | SVP | Sell | 1,626 | $189.20 | $307,639.20 | |
| 11/17/2014 | Roy A Whitfield | Director | Sell | 4,000 | $178.26 | $713,040.00 | |
| 11/14/2014 | Marc Stapley | CFO | Sell | 1,422 | $181.13 | $257,566.86 | |
| 11/13/2014 | Daniel Bradbury | Director | Sell | 2,100 | $186.88 | $392,448.00 | |
| 11/13/2014 | Jay T Flatley | CEO | Sell | 25,000 | $189.32 | $4,733,000.00 | |
| 11/3/2014 | Michel Bouchard | CAO | Sell | 631 | $195.68 | $123,474.08 | |
| 11/3/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $195.66 | $1,956,600.00 | |
| 10/30/2014 | Daniel Bradbury | Director | Sell | 2,100 | $191.83 | $402,843.00 | |
| 10/23/2014 | Jay T Flatley | CEO | Sell | 25,000 | $189.54 | $4,738,500.00 | |
| 10/13/2014 | Daniel Bradbury | Director | Sell | 2,100 | $152.03 | $319,263.00 | |
| 10/9/2014 | Jay T Flatley | CEO | Sell | 25,000 | $163.49 | $4,087,250.00 | |
| 10/7/2014 | A Blaine Bowman | Director | Sell | 4,456 | $159.51 | $710,776.56 | |
| 10/1/2014 | Daniel Bradbury | Director | Sell | 2,100 | $158.88 | $333,648.00 | |
| 10/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $159.81 | $1,598,100.00 | |
| 9/30/2014 | A Blaine Bowman | Director | Sell | 5,000 | $164.02 | $820,100.00 | |
| 9/29/2014 | Gerald Moeller | Director | Sell | 5,000 | $164.89 | $824,450.00 | |
| 9/25/2014 | Jay T Flatley | CEO | Sell | 25,000 | $164.43 | $4,110,750.00 | |
| 9/24/2014 | Christian O Henry | SVP | Sell | 20,000 | $167.28 | $3,345,600.00 | |
| 9/23/2014 | A Blaine Bowman | Director | Sell | 5,000 | $168.50 | $842,500.00 | |
| 9/16/2014 | A Blaine Bowman | Director | Sell | 5,000 | $169.60 | $848,000.00 | |
| 9/15/2014 | Daniel Bradbury | Director | Sell | 2,100 | $168.57 | $353,997.00 | |
| 9/15/2014 | Jay T Flatley | CEO | Sell | 25,000 | $176.06 | $4,401,500.00 | |
| 9/15/2014 | Marc Stapley | CFO | Sell | 1,422 | $169.05 | $240,389.10 | |
| 9/15/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $169.53 | $339,060.00 | |
| 9/9/2014 | A Blaine Bowman | Director | Sell | 5,000 | $178.08 | $890,400.00 | |
| 9/3/2014 | Christian O Henry | SVP | Sell | 10,000 | $180.59 | $1,805,900.00 | |
| 9/3/2014 | Daniel Bradbury | Director | Sell | 2,100 | $179.77 | $377,517.00 | |
| 9/2/2014 | A Blaine Bowman | Director | Sell | 5,000 | $179.67 | $898,350.00 | |
| 9/2/2014 | Michel Bouchard | VP | Sell | 686 | $180.07 | $123,528.02 | |
| 9/2/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $179.66 | $1,796,600.00 | |
| 8/28/2014 | Jay T Flatley | CEO | Sell | 30,000 | $178.98 | $5,369,400.00 | |
| 8/26/2014 | A Blaine Bowman | Director | Sell | 5,000 | $179.22 | $896,100.00 | |
| 8/22/2014 | Daniel Bradbury | Director | Sell | 2,100 | $172.24 | $361,704.00 | |
| 8/19/2014 | A Blaine Bowman | Director | Sell | 5,000 | $171.70 | $858,500.00 | |
| 8/15/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $167.23 | $334,460.00 | |
| 8/15/2014 | Roy A Whitfield | Director | Sell | 4,000 | $169.28 | $677,120.00 | |
| 8/13/2014 | Christian O Henry | SVP | Sell | 20,000 | $164.66 | $3,293,200.00 | |
| 8/5/2014 | A Blaine Bowman | Director | Sell | 5,000 | $159.91 | $799,550.00 | |
| 8/4/2014 | Daniel Bradbury | Director | Sell | 2,100 | $159.77 | $335,517.00 | |
| 8/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $159.73 | $1,597,300.00 | |
| 7/29/2014 | A Blaine Bowman | Director | Sell | 5,000 | $166.89 | $834,450.00 | |
| 7/29/2014 | Christian O Henry | SVP | Sell | 10,000 | $167.40 | $1,674,000.00 | |
| 7/24/2014 | Jay T Flatley | CEO | Sell | 30,000 | $175.43 | $5,262,900.00 | |
| 7/23/2014 | Daniel Bradbury | Director | Sell | 2,100 | $177.87 | $373,527.00 | |
| 7/15/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $174.26 | $348,520.00 | |
| 7/14/2014 | Marc Stapley | CFO | Sell | 1,422 | $177.59 | $252,532.98 | |
| 7/10/2014 | Jay T Flatley | CEO | Sell | 30,000 | $172.56 | $5,176,800.00 | |
| 7/8/2014 | Daniel Bradbury | Director | Sell | 2,100 | $172.89 | $363,069.00 | |
| 7/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $179.47 | $1,794,700.00 | |
| 6/30/2014 | Gerald Moeller | Director | Sell | 5,000 | $178.97 | $894,850.00 | |
| 6/27/2014 | Daniel Bradbury | Director | Sell | 2,100 | $171.65 | $360,465.00 | |
| 6/26/2014 | Jay T Flatley | CEO | Sell | 30,000 | $170.11 | $5,103,300.00 | |
| 6/24/2014 | Christian O Henry | SVP | Sell | 10,000 | $172.60 | $1,726,000.00 | |
| 6/16/2014 | Christian O Henry | SVP | Sell | 20,000 | $169.73 | $3,394,600.00 | |
| 6/16/2014 | Marc Stapley | CFO | Sell | 1,422 | $169.25 | $240,673.50 | |
| 6/12/2014 | Daniel Bradbury | Director | Sell | 2,100 | $171.17 | $359,457.00 | |
| 6/12/2014 | Jay T Flatley | CEO | Sell | 30,000 | $172.25 | $5,167,500.00 | |
| 6/2/2014 | Karin Eastham | Director | Sell | 6,000 | $157.56 | $945,360.00 | |
| 6/2/2014 | Michel Bouchard | CAO | Sell | 1,491 | $155.51 | $231,865.41 | |
| 6/2/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $156.93 | $1,569,300.00 | |
| 5/22/2014 | Jay Flatley | CEO | Sell | 30,000 | $154.95 | $4,648,500.00 | |
| 5/15/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $141.72 | $283,440.00 | |
| 5/15/2014 | Roy Whitfield | Director | Sell | 4,000 | $143.71 | $574,840.00 | |
| 5/14/2014 | Daniel Bradbury | Director | Sell | 2,100 | $146.46 | $307,566.00 | |
| 5/14/2014 | Marc Stapley | CFO | Sell | 1,422 | $146.94 | $208,948.68 | |
| 5/8/2014 | Jay Flatley | CEO | Sell | 30,000 | $143.59 | $4,307,700.00 | |
| 5/2/2014 | Daniel Bradbury | Director | Sell | 2,100 | $139.66 | $293,286.00 | |
| 5/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $135.91 | $1,359,100.00 | |
| 4/24/2014 | Jay Flatley | CEO | Sell | 30,000 | $150.80 | $4,524,000.00 | |
| 4/15/2014 | Daniel Bradbury | Director | Sell | 2,100 | $131.29 | $275,709.00 | |
| 4/15/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $133.56 | $267,120.00 | |
| 4/14/2014 | Marc Stapley | CFO | Sell | 1,422 | $134.80 | $191,685.60 | |
| 4/10/2014 | Jay Flatley | CEO | Sell | 30,000 | $139.90 | $4,197,000.00 | |
| 4/4/2014 | Daniel Bradbury | Director | Sell | 2,100 | $138.44 | $290,724.00 | |
| 4/1/2014 | Mostafa Ronaghi | SVP | Sell | 10,000 | $152.41 | $1,524,100.00 | |
| 3/27/2014 | Jay Flatley | CEO | Sell | 30,000 | $140.11 | $4,203,300.00 | |
| 3/19/2014 | Daniel Bradbury | Director | Sell | 2,100 | $161.14 | $338,394.00 | |
| 3/17/2014 | Gerald Moeller | Director | Sell | 10,000 | $161.92 | $1,619,200.00 | |
| 3/17/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $163.65 | $327,300.00 | |
| 3/14/2014 | Marc Stapley | CFO | Sell | 1,422 | $163.35 | $232,283.70 | |
| 3/13/2014 | Jay Flatley | CEO | Sell | 30,000 | $165.96 | $4,978,800.00 | |
| 3/11/2014 | Christian Henry | SVP | Sell | 3,000 | $167.16 | $501,480.00 | |
| 3/11/2014 | Michel Bouchard | CAO | Sell | 2,168 | $167.21 | $362,511.28 | |
| 3/3/2014 | Michel Bouchard | CAO | Sell | 2,994 | $176.81 | $529,369.14 | |
| 2/25/2014 | Michel Bouchard | CAO | Sell | 24,505 | $176.13 | $4,316,065.65 | |
| 2/24/2014 | Roy Whitfield | Director | Sell | 2,000 | $175.26 | $350,520.00 | |
| 2/18/2014 | Nicholas Naclerio | SVP | Sell | 2,000 | $169.77 | $339,540.00 | |
| 2/13/2014 | Jay Flatley | CEO | Sell | 30,000 | $160.43 | $4,812,900.00 | |
| 2/7/2014 | Jay Flatley | CEO | Sell | 5,000 | $152.23 | $761,150.00 | |
| 1/31/2014 | Marc Stapley | CFO | Sell | 20,038 | $151.32 | $3,032,150.16 | |
| 1/23/2014 | Jay Flatley | CEO | Sell | 30,000 | $142.30 | $4,269,000.00 | |
| 1/9/2014 | Jay Flatley | CEO | Sell | 30,000 | $114.77 | $3,443,100.00 | |
| 12/26/2013 | Jay Flatley | CEO | Sell | 30,000 | $107.88 | $3,236,400.00 | |
| 12/17/2013 | Gregory Heath | SVP | Sell | 1,875 | $102.68 | $192,525.00 | |
| 10/30/2013 | Christian O Henry | SVP | Sell | 6,000 | $93.29 | $559,740.00 | |
| 10/30/2013 | David R Walt | Director | Sell | 5,000 | $93.02 | $465,100.00 | |
| 10/28/2013 | William H Rastetter | Director | Sell | 20,000 | $92.37 | $1,847,400.00 | |
| 10/24/2013 | Jay T Flatley | CEO | Sell | 30,000 | $92.32 | $2,769,600.00 | |
| 10/22/2013 | Nicholas Naclerio | SVP | Sell | 20,000 | $90.00 | $1,800,000.00 | |
| 10/17/2013 | Gregory Heath | SVP | Sell | 1,875 | $82.09 | $153,918.75 | |
| 10/16/2013 | David R Walt | Director | Sell | 5,000 | $82.59 | $412,950.00 | |
| 10/15/2013 | Nicholas Naclerio | SVP | Sell | 4,000 | $81.32 | $325,280.00 | |
| 10/10/2013 | Christian Henry | SVP | Sell | 6,000 | $77.73 | $466,380.00 | |
| 10/10/2013 | Jay Flatley | CEO | Sell | 20,000 | $77.75 | $1,555,000.00 | |
| 10/2/2013 | David R Walt | Director | Sell | 5,000 | $80.58 | $402,900.00 | |
| 9/18/2013 | David Walt | Director | Sell | 5,000 | $83.11 | $415,550.00 | |
| 9/17/2013 | Gregory Heath | SVP | Sell | 1,875 | $85.20 | $159,750.00 | |
| 9/16/2013 | Jay Flatley | CEO | Sell | 30,000 | $83.27 | $2,498,100.00 | |
| 9/16/2013 | Nicholas Naclerio | SVP | Sell | 4,000 | $85.00 | $340,000.00 | |
| 9/10/2013 | Gregory Heath | SVP | Sell | 1,875 | $82.00 | $153,750.00 | |
| 9/9/2013 | Paul L Bianchi | SVP | Sell | 1,627 | $79.03 | $128,581.81 | |
| 9/5/2013 | Christian O Henry | SVP | Sell | 9,000 | $78.17 | $703,530.00 | |
| 9/4/2013 | David R Walt | Director | Sell | 5,000 | $77.18 | $385,900.00 | |
| 9/3/2013 | Nicholas Naclerio | SVP | Sell | 59,000 | $76.91 | $4,537,690.00 | |
| 9/3/2013 | Roy A Whitfield | Director | Sell | 2,000 | $78.49 | $156,980.00 | |
| 8/30/2013 | Mark Lewis | SVP | Sell | 5,000 | $78.12 | $390,600.00 | |
| 8/22/2013 | Jay Flatley | CEO | Sell | 20,000 | $78.65 | $1,573,000.00 | |
| 8/21/2013 | David Walt | Director | Sell | 5,000 | $78.34 | $391,700.00 | |
| 8/15/2013 | Nicholas Naclerio | SVP | Sell | 2,000 | $78.43 | $156,860.00 | |
| 8/8/2013 | Jay Flatley | CEO | Sell | 20,000 | $78.07 | $1,561,400.00 | |
| 8/7/2013 | David Walt | Director | Sell | 5,000 | $78.29 | $391,450.00 | |
| 8/2/2013 | Michel Bouchard | VP | Sell | 11,465 | $80.64 | $924,537.60 | |
| 7/25/2013 | Christian O Henry | SVP | Sell | 11,462 | $80.89 | $927,161.18 | |
| 7/25/2013 | Jay T Flatley | CEO | Sell | 20,000 | $81.01 | $1,620,200.00 | |
| 7/24/2013 | David R Walt | Director | Sell | 4,600 | $81.44 | $374,624.00 | |
| 7/24/2013 | Gregory Heath | SVP | Sell | 209,533 | $82.00 | $17,181,706.00 | |
| 7/24/2013 | Michel Bouchard | VP | Sell | 9,789 | $79.28 | $776,071.92 | |
| 7/15/2013 | Nicholas Naclerio | SVP | Sell | 2,000 | $74.50 | $149,000.00 | |
| 7/11/2013 | Jay T Flatley | CEO | Sell | 20,000 | $74.90 | $1,498,000.00 | |
| 7/11/2013 | Mostafa Ronaghi | SVP | Sell | 24,000 | $74.95 | $1,798,800.00 | |
| 7/10/2013 | David R Walt | Director | Sell | 5,000 | $74.26 | $371,300.00 | |
| 7/10/2013 | Michel Bouchard | VP | Sell | 3,618 | $74.30 | $268,817.40 | |
| 7/9/2013 | Christian O Henry | SVP | Sell | 9,000 | $74.01 | $666,090.00 | |
| 6/27/2013 | Jay T Flatley | CEO | Sell | 20,000 | $74.96 | $1,499,200.00 | |
| 6/26/2013 | David R Walt | Director | Sell | 5,000 | $75.36 | $376,800.00 | |
| 6/26/2013 | Michel Bouchard | VP | Sell | 4,272 | $75.06 | $320,656.32 | |
| 6/25/2013 | Tristan Orpin | SVP | Sell | 35,000 | $71.98 | $2,519,300.00 | |
| 6/17/2013 | Nicholas Naclerio | SVP | Sell | 2,000 | $68.56 | $137,120.00 | |
| 6/14/2013 | Christian O Henry | SVP | Sell | 25,959 | $68.10 | $1,767,807.90 | |
| 6/13/2013 | Jay T Flatley | CEO | Sell | 20,000 | $66.49 | $1,329,800.00 | |
| 6/13/2013 | Tristan Orpin | SVP | Sell | 47,667 | $66.55 | $3,172,238.85 | |
| 6/12/2013 | David R Walt | Director | Sell | 5,000 | $67.67 | $338,350.00 | |
| 6/12/2013 | Michel Bouchard | VP | Sell | 5,170 | $68.64 | $354,868.80 | |
| 6/11/2013 | Mostafa Ronaghi | SVP | Sell | 24,000 | $69.01 | $1,656,240.00 | |
| 6/3/2013 | Karin Eastham | Director | Sell | 10,000 | $70.34 | $703,400.00 | |
| 5/31/2013 | Mark L Lewis | SVP | Sell | 13,000 | $71.72 | $932,360.00 | |
| 5/30/2013 | Matthew L Posard | SVP | Sell | 2,836 | $70.80 | $200,788.80 | |
| 5/29/2013 | David R Walt | Director | Sell | 5,000 | $70.92 | $354,600.00 | |
| 5/29/2013 | Michel Bouchard | VP | Sell | 6,276 | $71.02 | $445,721.52 | |
| 5/21/2013 | Jay T Flatley | CEO | Sell | 24,000 | $69.39 | $1,665,360.00 | |
| 5/20/2013 | Marc Stapley | CFO | Sell | 2,843 | $73.38 | $208,619.34 | |
| 5/15/2013 | David R Walt | Director | Sell | 5,000 | $70.73 | $353,650.00 | |
| 5/15/2013 | Michel Bouchard | VP | Sell | 14,241 | $70.71 | $1,006,981.11 | |
| 5/15/2013 | Nicholas Naclerio | SVP | Sell | 2,000 | $70.72 | $141,440.00 | |
| 5/13/2013 | Mostafa Ronaghi | SVP | Sell | 24,000 | $68.83 | $1,651,920.00 | |
| 5/10/2013 | Tristan Orpin | SVP | Sell | 25,000 | $69.60 | $1,740,000.00 | |
| 5/9/2013 | Jay T Flatley | CEO | Sell | 20,000 | $66.63 | $1,332,600.00 | |
| 5/7/2013 | Tristan Orpin | SVP | Sell | 5,000 | $65.68 | $328,400.00 | |
| 4/8/2013 | Christian Cabou | SVP | Sell | 16,500 | $55.00 | $907,500.00 | |
| 4/8/2013 | Marc Stapley | CFO | Sell | 9,175 | $55.00 | $504,625.00 | |
| 4/8/2013 | William H Rastetter | Director | Sell | 20,000 | $54.95 | $1,099,000.00 | |
| 3/11/2013 | Marc Stapley | CFO | Sell | 4,468 | $53.71 | $239,976.28 | |
| 11/8/2012 | Jay T Flatley | CEO | Sell | 5,000 | $47.99 | $239,950.00 | |
(Data available from 1/1/2013 forward)
Headline Trends for Illumina (NASDAQ:ILMN)
Latest Headlines for Illumina (NASDAQ:ILMN)
| Source: |
|
| Date | Headline |
|---|
 | Insider Selling: Illumina, Inc. (ILMN) Director Sells 15,000 Shares of Stock
www.americanbankingnews.com - July 20 at 10:24 PM |
| Illumina, Inc. (NASDAQ:ILMN) EVP Marc Stapley Sells 2,000 Shares
www.americanbankingnews.com - July 17 at 10:14 PM |
 | 4 Tech Stocks Showing More Bite Than the FANGs - Investorplace.com
investorplace.com - July 17 at 3:48 PM |
 | ETFs with exposure to Illumina, Inc. : July 14, 2017
finance.yahoo.com - July 15 at 1:56 AM |
| 6 Growth Stocks That Will Outlast a Bear Market
finance.yahoo.com - July 13 at 3:07 AM |
| Illumina, Inc. (ILMN) Expected to Post Quarterly Sales of $642.50 Million
www.americanbankingnews.com - July 12 at 9:34 AM |
| Illumina to Announce Second Quarter 2017 Financial Results on Tuesday, August 1, 2017
finance.yahoo.com - July 11 at 11:48 PM |
| Omead Ostadan Sells 1,672 Shares of Illumina, Inc. (ILMN) Stock
www.americanbankingnews.com - July 11 at 10:52 PM |
| Illumina, Inc. (ILMN) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 11 at 5:30 PM |
| Illumina, Inc. (NASDAQ:ILMN) Rating Reiterated by Morgan Stanley
www.americanbankingnews.com - July 10 at 10:20 PM |
| Zacks: Brokerages Expect Illumina, Inc. (ILMN) to Post $0.68 EPS
www.americanbankingnews.com - July 10 at 8:08 PM |
 | Monday Sector Laggards: Services, Healthcare
www.nasdaq.com - July 10 at 7:47 PM |
| Jay T. Flatley Sells 15,000 Shares of Illumina, Inc. (ILMN) Stock
www.americanbankingnews.com - July 7 at 7:56 PM |
| 3 Charts That Every Illumina, Inc. Investor Needs to See
finance.yahoo.com - July 6 at 5:44 AM |
| Charles Dadswell Sells 145 Shares of Illumina, Inc. (NASDAQ:ILMN) Stock
www.americanbankingnews.com - July 5 at 10:44 PM |
| Illumina, Inc. (ILMN) Cut to Sell at BidaskClub
www.americanbankingnews.com - July 5 at 8:38 PM |
| Illumina, Inc. (NASDAQ:ILMN) Upgraded to Strong-Buy at Vetr Inc.
www.americanbankingnews.com - July 3 at 5:10 PM |
 | Better Buy: Illumina, Inc. vs. Roche Holding Ltd. (ADR) -- The Motley ... - Motley Fool
www.fool.com - July 2 at 12:22 AM |
 | Illumina (ILMN) Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit - StreetInsider.com
www.streetinsider.com - June 30 at 7:55 PM |
 | Illumina updates on cancer companion diagnostic test kit - Seeking Alpha
seekingalpha.com - June 30 at 7:55 PM |
| ETFs with exposure to Illumina, Inc. : June 30, 2017
finance.yahoo.com - June 30 at 7:55 PM |
| Illumina (ILMN) Granted FDA Approval for Next-Generation Sequencing Cancer Companion Diagnostic Test Kit
www.streetinsider.com - June 30 at 12:08 AM |
| Illumina Announces FDA-approved Next-Generation Sequencing Cancer Companion Diagnostic Test Kit
finance.yahoo.com - June 30 at 12:08 AM |
| If You Like Illumina, You'll Love Genomic Health - Seeking Alpha
seekingalpha.com - June 27 at 6:04 PM |
| Illumina, Inc. to Post FY2018 Earnings of $4.35 Per Share, Cantor Fitzgerald Forecasts (ILMN)
www.americanbankingnews.com - June 26 at 8:54 AM |
| Genomics England Adopts Illumina’s BaseSpace Variant Interpreter for Cancer
finance.yahoo.com - June 26 at 4:34 AM |
| Illumina, Inc. (ILMN) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - June 24 at 6:10 PM |
| IWP, ISRG, EA, ILMN: Large Outflows Detected at ETF
www.nasdaq.com - June 23 at 11:17 PM |
| Illumina, Inc. breached its 50 day moving average in a Bullish Manner : ILMN-US : June 23, 2017
finance.yahoo.com - June 23 at 11:17 PM |
| Illumina, Inc. (ILMN) Insider Sells $45,510.00 in Stock
www.americanbankingnews.com - June 23 at 10:34 PM |
| Illumina Shines as Another Biotech Winner
finance.yahoo.com - June 22 at 10:31 PM |
| Illumina, Inc. (ILMN) Director Jay T. Flatley Sells 20,000 Shares
www.americanbankingnews.com - June 22 at 7:26 PM |
| Vetr Inc. Downgrades Illumina, Inc. (ILMN) to Buy
www.americanbankingnews.com - June 22 at 12:34 AM |
| Boston Scientific Corporation (BSX) vs. Illumina (ILMN) Financial Survey
www.americanbankingnews.com - June 21 at 7:52 AM |
| Agree To Buy Illumina At $125, Earn 5.5% Using Options
www.nasdaq.com - June 20 at 6:46 PM |
| ETFs with exposure to Illumina, Inc. : June 19, 2017
finance.yahoo.com - June 19 at 4:51 PM |
 | Daily Technical Summary Reports on Biotech Stocks -- Illumina, Navidea Biopharma, Grifols, and Intercept Pharma
www.bizjournals.com - June 16 at 6:45 PM |
| Illumina, Inc. (ILMN) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 16 at 2:40 PM |
| Illumina, Inc. (ILMN) Expected to Announce Quarterly Sales of $642.50 Million
www.americanbankingnews.com - June 16 at 1:52 PM |
| Insider Selling: Illumina, Inc. (ILMN) EVP Sells 2,000 Shares of Stock
www.americanbankingnews.com - June 14 at 10:50 PM |
| $0.69 EPS Expected for Illumina, Inc. (ILMN) This Quarter
www.americanbankingnews.com - June 14 at 8:19 PM |
| Coalition for Access to Prenatal Screening Announces Clinical Advisory Board
finance.yahoo.com - June 13 at 10:56 AM |
| Illumina, Inc. (ILMN) Upgraded at Vetr Inc.
www.americanbankingnews.com - June 12 at 9:08 PM |
| Illumina, Inc. (ILMN) Insider Michel Bouchard Sells 246 Shares
www.americanbankingnews.com - June 9 at 4:15 PM |
| Illumina, Inc. (ILMN) Director Sells $3,604,800.00 in Stock
www.americanbankingnews.com - June 8 at 7:12 PM |
| SHAREHOLDER ALERT: Levi & Korsinsky, LLP Files Amended Complaint Against Illumina, Inc. and Senior Officers
finance.yahoo.com - June 8 at 6:50 PM |
| ETFs with exposure to Illumina, Inc. : June 8, 2017
finance.yahoo.com - June 8 at 6:50 PM |
| Illumina Inc. Stock History: The Genomic-Sequencing Leader's Path to Success
finance.yahoo.com - June 8 at 6:50 PM |
| Illumina, Inc. (ILMN) SVP Charles Dadswell Sells 145 Shares
www.americanbankingnews.com - June 7 at 8:21 PM |
| Pasadena epigenetics startup raises money to improve male reproductive health
www.bizjournals.com - June 6 at 11:34 AM |
Illumina (ILMN) Chart for Friday, July, 21, 2017
